The molecular mechanisms and signaling pathways underlying these benefits are complex and multifaceted, encompassing direct interactions with gut microbiota, strengthening of gut barrier function, modulation of immune responses, and attenuation of systemic inflammation
Blended peptide formulations such as KLOW are examined in controlled laboratory research to explore: Published research relating to individual components can be found on scientific databases such as PubMed
They found that for FDA approved GLP-1s for weight loss, liraglutide (Saxenda) and semaglutide (Wegovy), the percent of side effects reported was as follows: Nausea: 42.2% Diarrhea: 21.9% Vomiting: also 21.9% Constipation: 8.4% They report that although the incidence of side effects were similar among medications, semaglutide had the greatest risk of nausea, diarrhea, and vomiting, whereas liraglutide had the greatest risk of upper abdominal pain
There was never a reason to include them
Metabolic/bariatric surgery also modifies bone microarchitecture and strength, and increases the risk of fracture [10,11,12]
Whilst taste changes associated with GLP-1 medications are generally benign and self-limiting, certain circumstances warrant medical review